Streetbeat News

Products Services

TERN

Terns Pharmaceuticals has received FDA Orphan Drug Designation for TERN-701, aimed at treating Chronic Myeloid Leukemia. TERN-701 is a BCR-ABL tyrosine kinase inhibitor currently in Phase 1 clinical trials, with interim results expected in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:06 pm

ALTO

Alto Ingredients has announced its intention to collaborate with Vault on a carbon capture and storage initiative. As part of this initiative, Alto will install equipment to capture carbon dioxide generated from its production process at its Pekin campus. Vault will then be responsible for the transportation and storage of these emissions.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:04 pm

TSLA

Tesla has increased the price of its Model Y and Model Y Long Range in the U.S. by $1,000 each, now priced at $43,990 and $48,990 respectively, according to Reuters citing Tesla's website.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 7:50 pm

ABT

The FDA has announced that Abbott is recalling its Heartmate Touch Communication System (version 1.0.32) due to the risk of the device unexpectedly starting or stopping. This recall has been classified as a Class I recall, indicating a situation where there is a reasonable probability that the use of or exposure to the violative product will cause serious adverse health consequences or death. There have been 8 reported injuries associated with this issue, but no deaths have been reported.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 7:49 pm

BLK

BTCUSD

Mudrex introduced U.S. Bitcoin Spot ETFs to Indian investors, featuring ETFs from BlackRock Inc. (NYSE:BLK), Fidelity, Franklin Templeton, and Vanguard. This allows Indian investors to engage with Bitcoin through a regulated framework, with investments ranging from $5,000 to $250,000. Mudrex, licensed in Lithuania and Italy, adheres to regulatory frameworks in India and the EU.

Portfolio Pulse from Murtuza Merchant

March 11, 2024 | 7:45 pm

TSLA

Aswath Damodaran, a prominent finance professor, recently purchased Tesla Inc (NASDAQ:TSLA) stock at $180, sparking discussions among investors on Reddit's r/ValueInvesting about Tesla's valuation. While some Redditors see Damodaran's purchase as timely, citing his expertise in valuation and Tesla's diversified offerings, others express caution due to concerns over Tesla's P/E ratio, economic challenges in China, and uncertainties around Model 3 refresh qualifications for tax credits. Technical analysis suggests potential support for Tesla's stock at $160.

Portfolio Pulse from Surbhi Jain

March 11, 2024 | 7:27 pm

NFLX

Financial analysis reveals a bearish sentiment in Netflix's (NASDAQ:NFLX) options market, with 67% of trades showing bearish tendencies. The analysis highlighted unusual trading activity, including 143 trades with a focus on a price band between $40.0 and $1000.0. The largest trades included both bearish and bullish sentiments, with significant activity around the $290.00 strike price. Netflix, with its vast subscriber base and recent move into ad-supported plans, is currently trading up by 0.54% at $608.08, with analysts setting an average price target of $705.0.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 7:15 pm

STI

Solidion Technology Inc (NASDAQ:STI) shares surged by 130% to $1.80, despite no company-specific news. The increase may be attributed to post-IPO volatility, following its debut in February after a merger. The company is focusing on electric vertical takeoff and landing (eVTOL) aircraft technology, highlighting its advancements in lithium-sulfur batteries, with over 100 US patents. Solidion is seeking partnerships to commercialize this technology. Additionally, Solidion pays a dividend yielding 3.34% as of Mar. 11, 2024.

Portfolio Pulse from Henry Khederian

March 11, 2024 | 6:59 pm

PFE

Pfizer Inc (NYSE:PFE) is shifting its strategic focus from COVID-19 to cancer drugs, aiming to recover from a significant market value loss. The company plans to increase its oncology biologic drugs from 6% to 65% by 2030, following a challenging period with over $100 billion in market value lost. Pfizer's acquisition of Seagen doubles its oncology pipeline to 60 programs, with expectations of eight blockbuster medicines by 2030. The company also focuses on expanding its respiratory syncytial virus vaccine and developing treatments for sickle cell disease and obesity.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 6:51 pm

ASLN

Piper Sandler released a note on ASLAN Pharmaceuticals, indicating the company's belief in the value and differentiation of its once-monthly subcutaneous Eblasakimab compared to Dupixent, which is administered every other week. This suggests ASLAN Pharmaceuticals is open to partnerships or acquisition based on the unique positioning of Eblasakimab.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:45 pm